Lisinopril Tablets Recalled for Stray Amlodipine Tablet Contamination
NCS Healthcare recalled Lisinopril Tablets USP 20 mg nationwide due to potential presence of stray Amlodipine Besylate 10 mg tablets in certain lots. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard—stray tablets of a different pharmaceutical—presents a potential medication error risk, but the classification as Class III combined with the absence of reported patient harm places this in the low-risk contamination category.
Plain-English summary
NCS Healthcare of Kentucky Inc is recalling Lisinopril Tablets USP 20 mg (15-count and 30-count blister cards) due to the potential presence of stray Amlodipine Besylate 10 mg tablets within certain lots. The affected lot is number 8255-3012 with expiration date 08/31/2024.
The recall affects customers nationwide. Patients who may have received affected product should verify they have the correct medication. Any patient or healthcare provider who believes they have received affected product should contact their pharmacy or healthcare provider.
Patients currently taking Lisinopril or Amlodipine should continue their medication as prescribed and consult their healthcare provider if they have questions about the safety or authenticity of their medication.
The recalled product
- Product
- BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)
- Brand
- BUSPIRONE HYDROCHLORIDE
- Manufacturer
- NCS Healthcare of Kentucky Inc
- Category
- Drug
- Hazard
- foreign-tablets
- medication-error
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot#: a) 8255-3012
- Exp 08/31/2024
- b) 8255-3012
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUSPIRONE HYDROCHLORIDE
- LowBuspirone Hydrochloride Tablets 5 mg Recalled for Subpotency
FDA (Drugs) · 2026-05-13
- HighBuspirone Hydrochloride Tablets Recalled Due To Amlodipine Contamination Risk
FDA (Drugs) · 2023-11-29
- ModerateDrug Recall: Buspirone Tablets Over Manufacturing Process Deviations
FDA (Drugs) · 2023-05-03
- HighFDA recalls Buspirone Hydrochloride tablets for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAccord Healthcare Recalls Buspirone Hydrochloride Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27